查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1159158

化疗诱发性嗜中性白血球低下症治疗的全球市场(2022年～2028年)

Chemotherapy-Induced Neutropenia Treatment Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

全球化疗诱发性嗜中性白血球低下症治疗的市场规模在预测期间内预计将以大幅年复合成长率增长。化疗在癌症治疗中的广泛应用、全球癌症患病率的上升以及政府政策增加导致的市场进入者数量的增加正在推动市场的增长。

本报告提供全球化疗诱发性嗜中性白血球低下症治疗市场相关调查分析，提供市场概要，竞争情形，市场分析，企业简介等系统性资讯。

目录

第1章 报告概要

第2章 市场概要与洞察

  • 调查范围
  • 分析师的洞察和目前市场趋势

第3章 竞争情形

  • Amgen Inc.
  • BeyondSpring Inc.
  • Cellerant Therapeutics Inc.
  • Kyowa Kirin Co. Ltd.
  • Mylan Pharmaceutical Pvt. Ltd.
  • 主要策略分析
  • COVID-19对主要企业带来的影响

第4章 市场区隔

  • 全球化疗诱发性嗜中性白血球低下症治疗市场:各治疗类型
    • 抗生素疗法
    • 集落刺激因子治疗
    • 粒细胞输注
    • 脾臟切除手术
    • 其他
  • 全球化疗诱发性嗜中性白血球低下症治疗市场:各流通管道
    • 医院药局
    • 零售药局
    • 线上药局

第5章 地区分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 全球其他地区

第6章 企业简介

  • Novartis AG
  • Partner Therapeutics Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Coherus Biosciences Inc.
Product Code: OMR2025712

Global Chemotherapy-Induced Neutropenia Treatment Market Size, Share & Trends Analysis Report by Therapy Type (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Transfusion, and Others), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast 2022-2028

The global chemotherapy-induced neutropenia treatment market is anticipated to grow at a significant CAGR during the forecast period. Chemotherapy-induced neutropenia is a cancer-related side effect that directly affects the bone marrow. Patients who have developed neutropenia as a result of chemotherapy must be admitted to the hospital. Furthermore, as an anti-infective medication is employed, the cost of treatment grows. The key driver of market growth is the growing use of chemotherapy for cancer treatment, as well as the rising prevalence of cancer around the world. According to the National Cancer Institute (NCI), there will be 1,806,590 new cancer cases diagnosed in the United States in 2020, with a 606,520 deaths rate. The most common cancers include breast cancer, lung and bronchus cancer, and leukemia, among others. In 2020, prostate, lung, and colorectal cancers will account for around 43% of all new cancer diagnoses in men, while breast, lung, and colorectal cancers will account for almost 50% of all new cancer diagnoses in women.

The global chemotherapy-induced neutropenia treatment market is segmented based on the therapy type and distribution channel. Based on the type, the market is sub-segmented into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, splenectomy procedure, and others. Based on the distribution channel, the global chemotherapy-induced neutropenia treatment market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, colony-stimulating factor therapy is expected to propel the growth of the market, due to its ability to help bone marrow produce more white blood cells.

The global chemotherapy-induced neutropenia treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among the regions, the Asia-Pacific region in the global chemotherapy-Induced neutropenia treatment market is expected to hold a prominent market share due to the presence of several key market players. For Instance, in December 2021, Lupin Pharmaceuticals, Inc. signed an agreement with Biomm SA for the distribution of Pegfilgrastim in Brazil. Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Additionally, the surge in government policies is now allowing many players to come into the market with their innovative products.

The major companies serving the global chemotherapy-induced neutropenia treatment market include Amgen, Inc., Sanofi S.A., Novartis International AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2019, GSK completed the acquisition of TESARO, an oncology-focused biopharmaceutical company. It will strengthen GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in the oncology

Research Methodology

The market study of the global chemotherapy-induced neutropenia treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalogue.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Solar Carport Charging Station Market Research and Analysis by Therapy Type.

2. Global Solar Carport Charging Station Market Research and Analysis by Distribution Channel.

The Report Covers:

  • Comprehensive Research Methodology of the global chemotherapy-induced neutropenia treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global chemotherapy-induced neutropenia treatment market.
  • Insights about market determinants that are stimulating the global chemotherapy-induced neutropenia treatment market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Chemotherapy-Induced Neutropenia Treatment Market
  • Recovery Scenario of Global Chemotherapy-Induced Neutropenia Treatment Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Amgen Inc.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. BeyondSpring Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Cellerant Therapeutics Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Kyowa Kirin Co. Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Mylan Pharmaceutical Pvt. Ltd.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Chemotherapy-Induced Neutropenia Treatment Market by Therapy Type
    • 4.1.1. Antibiotic Therapy
    • 4.1.2. Colony-Stimulating Factor Therapy
    • 4.1.3. Granulocyte Transfusion
    • 4.1.4. Splenectomy Procedure
    • 4.1.5. Others
  • 4.2. Global Chemotherapy-Induced Neutropenia Treatment Market by Distribution Channel
    • 4.2.1. Hospital Pharmacy
    • 4.2.2. Retail Pharmacy
    • 4.2.3. Online Pharmacy

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Novartis AG
  • 6.2. Partner Therapeutics Inc.
  • 6.3. Pfizer Inc.
  • 6.4. Spectrum Pharmaceuticals Inc.
  • 6.5. Teva Pharmaceutical Industries Ltd.
  • 6.6. Coherus Biosciences Inc.

LIST OF TABLES

  • 1. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL ANTIBIOTIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL COLONY-STIMULATING FACTOR CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL GRANULOCYTE TRANSFUSION CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL SPLENECTOMY PROCEDURE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL OTHERS CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 8. GLOBAL HOSPITAL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL RETAIL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL ONLINE PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 15. EUROPEAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET, 2021-2028 (%)
  • 4. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY THERAPY TYPE, 2021 VS 2027 (%)
  • 5. GLOBAL ANTIBIOTIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL COLONY-STIMULATING FACTOR CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL GRANULOCYTE TRANSFUSION CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL SPLENECTOMY PROCEDURE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL OTHERS CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
  • 11. GLOBAL HOSPITAL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL RETAIL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL ONLINE PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. REST OF THE ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)